Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Dyskinesias, Parkinson Disease

In brief

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

Key facts

Study ID

NCT04377945

Run by

Bukwang Pharmaceutical

People needed

41

Starts

2021-04-28

Expected to finish

2024-02-14

Last updated by the study team

2024-06-17

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is able to read, understand, and provide written, dated informed consent prior to Screening Visit.
• Is male or female, between 18 and 85 years of age at Screening Visit.
• Is diagnosed with idiopathic PD that meets UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria
• Has experienced dyskinesia
• Has stable peak-effect dyskinesia
• Has more than one hour of "ON" time with troublesome dyskinesia

You may not qualify if…

• Has undergone surgery for the treatment of PD
• Has a current diagnosis of Substance Use
• Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses
• Has current seizure disorders requiring treatment with anticonvulsants.
• Other criteria related to other medical conditions to be referred to the protocol.

Where it is running

• Bukwang Investigator site — Miami, Florida, United States
• Bukwang Investigator site — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.